Related Experiment Video
Updated: Jun 8, 2026

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
Published on: May 8, 2018
Advanced glycation endproducts and their pathogenic roles in neurological disorders
Gerald Münch1, Bernadette Westcott, Teresita Menini
1Molecular Medicine Research Group, Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, NSW, 2560, Australia. g.muench@uws.edu.au
Abstract:
Glycation is implicated in neurological disorders. In some cases it plays a key role in the pathogenesis, in others it plays a co-adjuvant role or it appears as a consequence of degenerative changes and protein accumulation stemming from other pathways. In this work, we attempt to provide a concise, updated review of the major recent findings concerning glycation in neurological diseases. After a short introduction covering advanced glycation endproducts (AGEs) and the receptor for AGEs (RAGE), we will discuss the impact of glycation in central nervous system disorders including Alzheimer's, Parkinson's and Creutzfeldt-Jakob disease, as well as peripheral diabetic polyneuropathies. Therapies directed at lowering the concentrations of RAGE ligands including AGEs, blocking RAGE signaling, preventing oxidative stress or lowering methylglyoxal (MGO) levels may significantly decrease the development of AGE-related pathologies in patients with neurological disorders. Many drugs are on the pipeline and the future clinical trials will reveal if the promising results translate into clinical application.
More Related Videos
Related Concept Videos
Diabetic Neuropathy
Parkinson Disease ll: Pathophysiology
Proteoglycans
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

